Cargando…

Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies

Cannabinoids are lipophilic substances derived from Cannabis sativa that can exert a variety of effects in the human body. They have been studied in cellular and animal models as well as in human clinical trials for their therapeutic benefits in several human diseases. Some of these include central...

Descripción completa

Detalles Bibliográficos
Autores principales: Duncan, R. Scott, Riordan, Sean M., Gernon, Matthew C., Koulen, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664133/
https://www.ncbi.nlm.nih.gov/pubmed/37843213
http://dx.doi.org/10.4103/1673-5374.382220
_version_ 1785138550309650432
author Duncan, R. Scott
Riordan, Sean M.
Gernon, Matthew C.
Koulen, Peter
author_facet Duncan, R. Scott
Riordan, Sean M.
Gernon, Matthew C.
Koulen, Peter
author_sort Duncan, R. Scott
collection PubMed
description Cannabinoids are lipophilic substances derived from Cannabis sativa that can exert a variety of effects in the human body. They have been studied in cellular and animal models as well as in human clinical trials for their therapeutic benefits in several human diseases. Some of these include central nervous system (CNS) diseases and dysfunctions such as forms of epilepsy, multiple sclerosis, Parkinson’s disease, pain and neuropsychiatric disorders. In addition, the endogenously produced cannabinoid lipids, endocannabinoids, are critical for normal CNS function, and if controlled or modified, may represent an additional therapeutic avenue for CNS diseases. This review discusses in vitro cellular, ex vivo tissue and in vivo animal model studies on cannabinoids and their utility as therapeutics in multiple CNS pathologies. In addition, the review provides an overview on the use of cannabinoids in human clinical trials for a variety of CNS diseases. Cannabinoids and endocannabinoids hold promise for use as disease modifiers and therapeutic agents for the prevention or treatment of neurodegenerative diseases and neurological disorders.
format Online
Article
Text
id pubmed-10664133
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-106641332023-08-14 Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies Duncan, R. Scott Riordan, Sean M. Gernon, Matthew C. Koulen, Peter Neural Regen Res Review Cannabinoids are lipophilic substances derived from Cannabis sativa that can exert a variety of effects in the human body. They have been studied in cellular and animal models as well as in human clinical trials for their therapeutic benefits in several human diseases. Some of these include central nervous system (CNS) diseases and dysfunctions such as forms of epilepsy, multiple sclerosis, Parkinson’s disease, pain and neuropsychiatric disorders. In addition, the endogenously produced cannabinoid lipids, endocannabinoids, are critical for normal CNS function, and if controlled or modified, may represent an additional therapeutic avenue for CNS diseases. This review discusses in vitro cellular, ex vivo tissue and in vivo animal model studies on cannabinoids and their utility as therapeutics in multiple CNS pathologies. In addition, the review provides an overview on the use of cannabinoids in human clinical trials for a variety of CNS diseases. Cannabinoids and endocannabinoids hold promise for use as disease modifiers and therapeutic agents for the prevention or treatment of neurodegenerative diseases and neurological disorders. Wolters Kluwer - Medknow 2023-08-14 /pmc/articles/PMC10664133/ /pubmed/37843213 http://dx.doi.org/10.4103/1673-5374.382220 Text en Copyright: © Neural Regeneration Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review
Duncan, R. Scott
Riordan, Sean M.
Gernon, Matthew C.
Koulen, Peter
Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies
title Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies
title_full Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies
title_fullStr Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies
title_full_unstemmed Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies
title_short Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies
title_sort cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664133/
https://www.ncbi.nlm.nih.gov/pubmed/37843213
http://dx.doi.org/10.4103/1673-5374.382220
work_keys_str_mv AT duncanrscott cannabinoidsandendocannabinoidsastherapeuticsfornervoussystemdisorderspreclinicalmodelsandclinicalstudies
AT riordanseanm cannabinoidsandendocannabinoidsastherapeuticsfornervoussystemdisorderspreclinicalmodelsandclinicalstudies
AT gernonmatthewc cannabinoidsandendocannabinoidsastherapeuticsfornervoussystemdisorderspreclinicalmodelsandclinicalstudies
AT koulenpeter cannabinoidsandendocannabinoidsastherapeuticsfornervoussystemdisorderspreclinicalmodelsandclinicalstudies